Dr. Joel Picus, MD

Dr. Picus practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Picus' NPI, 1932125259, was assigned on July 14, 2006. Dr. Picus graduated from Harvard Medical School in 1984. Dr. Picus holds Missouri license R1P41.

Dr. Picus' primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Picus also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Picus' primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Picus is also affiliated with Barnes-Jewish West County Hospital. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Picus to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Picus practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Picus' primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Picus is licensed in Missouri.

CMS data shows 726 Medicare services from Dr. Picus across 11 procedure codes in 2024, for 192 Medicare patients. Medicare paid $21,443 for them. Every service was in an office.

CMS counts 192 Medicare patients who saw Dr. Picus in 2024. The largest group is 75 to 84, with 85 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.69, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Picus' median patient age at 76, with 8% women.

In 2024, Dr. Picus wrote 631 Medicare Part D claims for 77 patients. 48% of them were for generic drugs. CMS names the drug for 579 of them, across 13 drugs with 11 or more claims each, at $4,250,173 in total drug cost. In 2023, CMS named 660 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Picus for performance year 2024, reported as part of a group. Dr. Picus accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 57 papers to Dr. Picus, published from 2010 to 2024. 2018 was the busiest year, with 7. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents and Docetaxel. Dr. Picus has published most often in Clin Cancer Res. Dr. Picus' most frequent co-authors are Noah M. Hahn, MD, Rama Suresh, MD and Charles Erlichman, MD.

Dmand AI links Dr. Picus to 11 clinical trials, 5 of them phase 3 studies. 8 are still active or recruiting. Conditions studied include Carcinoma, Renal Cell, Kidney Neoplasms and Ureteral Neoplasms. National Cancer Institute (NCI) sponsors the most, 4. Open Payments lists research payments to Dr. Picus that name 1 trial.

CMS Open Payments shows 12 general payments to Dr. Picus from 5 drug and device companies from 2016 to 2020. Consulting fees make up the largest share, 93% of the total. Novo Nordisk AS paid the most, $27,440. It also lists 40 research payments totaling $41,339 from 2018 to 2019, naming 1 clinical trial.

Dr. Picus graduated from Harvard Medical School in 1984.